Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| 8-K | Sep 23, 2026 | 2026-09-23 17:03:03 | View |
| 8-K | Sep 9, 2026 | 2026-09-09 17:21:44 | View |
| 4 | Sep 4, 2026 | 2026-09-04 17:00:38 | View |
| 4 | Aug 4, 2026 | 2026-08-04 17:00:54 | View |
| 4 | Aug 4, 2026 | 2026-08-04 17:00:13 | View |
| 144 | Aug 3, 2026 | 2026-08-03 20:14:29 | View |
| 144 | Jul 31, 2026 | 2026-07-31 20:04:20 | View |
| 4 | Jul 31, 2026 | 2026-07-31 17:04:00 | View |
| 4 | Jul 31, 2026 | 2026-07-31 17:03:18 | View |
| 4 | Jul 31, 2026 | 2026-07-31 17:02:07 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 2, 26 | Berkshire James G. | officer: See Remarks | M-Exempt | 5,381 @ $131.82 | $709.3K |
| Sep 2, 26 | Berkshire James G. | officer: See Remarks | S-Sale | 2,668 @ $261.33 | $697.2K |
| Sep 2, 26 | Berkshire James G. | officer: See Remarks | D-Return | 2,713 @ $261.54 | $709.6K |
| Sep 2, 26 | Berkshire James G. | officer: See Remarks | M-Exempt | 5,381 @ $131.82 | $709.3K |
| Aug 3, 26 | Staub W Richard | officer: See Remarks | S-Sale | 5,500 @ $232.68 | $1.28M |
| Jul 31, 26 | Patel Bhavik | officer: See Remarks | S-Sale | 1,855 @ $235.27 | $436.4K |
| Jul 29, 26 | Sherbet Eric | officer: See Remarks | S-Sale | 5,000 @ $249.16 | $1.25M |
| Jul 29, 26 | Cherofsky Keriann | officer: See Remarks | S-Sale | 558 @ $245.21 | $136.8K |
FY2025 · 10-K disclosure
FY2025 · 10-K disclosure
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 65.28 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 89.71 | Oscillator | Sell |
| Williams %R (14) | -12.92 | Oscillator | Sell |
| MACD (12, 26, 9) | 3.69 (Hist 1.39) | Oscillator | Strong Buy |
| Average Directional Index (14) | 27.48 (+DI 27.2 / -DI 9.3) | Trend | Strong Buy |
Stock news · updated daily
IQV is poised for y/y revenue and earnings growth in Q3, driven by stronger clinical research demand, solid bookings, AI adoption and operational efficiencies.
IQVIA Holdings (IQV) is rated Buy, supported by strong Q2 results and a robust R&D bookings recovery. Q2 revenue grew 8.7% to $4.37B, with adjusted EPS up 12.1% and R&D net new bookings surging 19% to $3.15B. Commercial Solutions delivered 8.6% revenue growth, with AI adoption and data assets driving margin expansion and cross-selling opportunities.
TTM vs. 5-year historical average (annual ratios)
| Metric | IQV | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 34.3x | 35.4x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | 21.6x | EPS est. 12.94 | Discount |
| Price / Book | 7.6x | 6.9x | In line |
| Price / Sales | 2.7x | 2.8x | In line |
| EV / EBITDA | 17.1x | 17.9x | In line |
| Return on equity | 22.0% | — | Top tier |
| Gross margin | 26.2% | 34.3% | Below hist. |
| Debt / Equity | 2.63 | 2.28 | Levered |
| Piotroski / Altman Z | 7/9 | Z 2.25 | Grey zone |
Discounted cash flow model
| EMA 20 | 267.90 | MA | Strong Buy |
| SMA 20 | 266.06 | MA | Strong Buy |
| EMA 50 | 258.38 | MA | Strong Buy |
| SMA 50 | 263.22 | MA | Strong Buy |
| SMA 200 | 208.73 | MA | Strong Buy |
IQVIA (IQV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Jul 28, 2026 | 3.03 | 3.15 | Beat 4.0% | $4.37B |
| May 5, 2026 | 2.82 | 2.90 | Beat 2.8% | $4.15B |
| Feb 5, 2026 | 3.40 | 3.42 | Beat 0.6% | $4.36B |
| Oct 28, 2025 | 2.98 | 3.00 | Beat 0.7% | $4.10B |
| Jul 22, 2025 | 2.77 | 2.81 | Beat 1.4% | $4.02B |
| May 6, 2025 | 2.63 | 2.70 | Beat 2.7% | $3.83B |
Current price $279.09
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Oct 14, 26 | Stifel | maintain | Buy | Buy |
| Oct 7, 26 | Mizuho | maintain | Outperform | Outperform |
| Oct 7, 26 | Barclays | maintain | Overweight | Overweight |
| Sep 29, 26 | RBC Capital | maintain | Outperform | Outperform |
| Sep 28, 26 | Truist Securities | maintain | Buy | Buy |
| Sep 17, 26 | Morgan Stanley | maintain | Equal Weight | Equal Weight |
| Jul 29, 26 | RBC Capital | maintain | Outperform | Outperform |
| Jul 29, 26 | Baird | maintain | Outperform | Outperform |
| Jul 29, 26 | BMO Capital | maintain | Outperform | Outperform |